LY2940680_1258861-20-9_MSDS_MedChemExpress

合集下载

EL-102_SDS_MedChemExpress

EL-102_SDS_MedChemExpress

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :EL-102Catalog No. :HY-16187CAS No. :1233948-61-21.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:EL 102; EL102Formula:C19H16N2O3S2Molecular Weight:384.47CAS No. :1233948-61-24. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Light yellow to yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

亿迈林

亿迈林
IP (n = 77) EP (n = 77)
北美 / 澳大利亚
IP
Survival Median (95% CI) 1年生存率 2年生存率
IP 12.8 月 58.4% 19.5%
EP 9.4 月 37.7% 5.2%
IP 9.3 月 35% 8.0%
EP 10.2 月 35.2% 7.9%
结论
广泛期SCLC治疗中,IP方案在有效 率和中位生存期方面优于EP方案
伊立替康小细胞肺癌推荐方案

伊立替康 60 mg/m2 d1, 8, 15 DDP 60 mg/m2 day 1 Q4 weeks x 4 cycles

伊立替康 65 mg/m2 d1,8 DDP 30 mg/m2 days 1, 8 Q3 weeks x 4 cycles
谢 谢!
伊立替康 65 mg/m2 d1,8 DDP 30 mg/m2 days 1, 8 Q3 weeks x 4 cycles
2:1
伊立替康总剂量 520mg/m2
VP-16 100 mg/m2 days 1-3 DDP 80 mg/m2 day 1 Q3 weeks x 4 cycles
VP-16 120 mg/m2 days 1-3 DDP 60 mg/m2 day 1 Q3 weeks x 4 cycles
亿迈林
---伊立替康注射液
亿迈林简介
商品名:亿迈林 通用名:盐酸伊立替康注射液 英文名:Irinotecan Hydrochloride Injection 生产企业:齐鲁制药(海南)有限公司
伊立替康注射液
(1)2ml:40mg;(2)5ml:100mg
伊立替康作用机理

伊立替康,为喜树碱类抗肿瘤药物,作用靶点是拓 扑异构酶I 伊立替康经羧酸酯酶转化为SN-38,为主要活性代 谢产物 伊立替康和SN-38可诱导单链DNA损伤,从而阻断 DNA复制,产生细胞毒性。这种细胞毒性为时间 依赖性,并特异性作用于S期,为细胞周期特异性 药物

高效液相色谱法测定注射用美罗培南的有关物质

高效液相色谱法测定注射用美罗培南的有关物质

第35卷第3期 长治医学院学报2021 年 6 月JOURNAL OF CHANGZHI MEDICAI COLLEGE167Vol. 35 No. 3Jun. 2021高效液相色谱法测定注射用美罗培南的有关物质李金格禹玉洪**作者单位山西医科大学药学院药剂教研室(030001)* 通信作者(E-mail :3024546064@ qq. com)摘要目的:探讨优化注射用美罗培南杂质A 、B 的测定方法。

方法:运用高效液相色谱法(HPLC) 进行检测,色谱柱以十八烷基硅烷键合硅胶为填充剂;流动相A :20. 0 mmol-L'1磷酸二氢钠-甲醇(89 :11, V/V),流动相B :甲醇,流速1.0 mL-min 1,检测波长220 nm,柱温30 P 。

结果:主成分峰与杂质峰可实现基线分离,杂质A 检测限和定量限分别为1. 62,5.15 ng,杂质B 检测限和定量限分别为0. 85,2. 51 ng ;1.2~24.0 ixg-mL -1的杂质A 具有良好的线性关系(r=0. 999 9) ,0.7-14.0 ixg-mL 1的杂质B 具有良好的线性 关系(r=0. 999 9);杂质A 平均加样回收率为101.2%(RSD= 1.38%,“ = 9),杂质B 平均加样回收率为100.2%(RSD=1.29%,n = 9)o 经破坏性试验,美罗培南可能的降解杂质A 、B 均不干扰美罗培南主峰的测定。

结论:检测限及定量限、精密度、稳定性、耐用性试验结果均符合HPLC 有关物质测定的方法学验证要求。

本HPLC 法专属性良好,可用于美罗培南的主要杂质A 、B 的定量控制。

关键词美罗培南;有关物质;高效液相色谱法中图分类号R97&1文献标识码 A 文章编号1006(2021)03-167-05Determination of Related Substances of Meropenem for Injection by High Performance Liquid ChromatographyLI Jinge , YU YuhongDepartment of Pharmacy , School of Pharmacy , Shanxi Medical UniversityAbstract Objective : To explore and optimize the determination method of impulity A andB of meropenem for injection. Meth ­ods :Using the high performance liquid chromatography ( HPLC ) to detection , Octadecylsilane-bonded silica gel was used as the fi ­ler ; The mobile phase A : 20. 0 mmol * L -1 sodium dihydrogen phosphate-methanol ( 89 : 11, V/V) . The mobile phase B : methanol ,the flow rate was 1. 0 mL *m in _1 and the detection wavelength was set at 220 nm. The column temperature was set at 30 % . Re ­sults :The principal component peak and impurity peak could achieve baseline separation. The detection limit and quantitative limit of impurity A were 1. 62 ng and 5. 15 ng respectively , and the detection limit and quantitative lim 让 of impurity B were 0. 85 ng and 2. 51 ng respectively. There was A good linear relationship between impurity A (r = 0. 999 9) and impurity B ( r= 0. 999 9 ) in therange of 1. 2-24. 0 |xg *m L _1 and 0. 7 ~ 14. 0 jig * mL -1. The average recovery of impurity A was 101. 2% ( RSD = 1. 38% , n = 9),and that of impurity B was 100. 2% ( RSD = 1. 29% , n= 9). After stressing test, both of impurities A and B of meropenem didn * tinterfere w 让h the determination of meropenem main peak. Conclusion : The test results of detection lim 让 and quant N ative lim 让,pre ­cision ,stabil 让y and durability all meet the methodological verification requirements of HPLC related substance determination. The HPLC method has good specificity and can be used for the quant N ative control of major impurities A and B.Key words meropenem ; related substances ; HPLC注射用美罗培南(Meropenem, C ”H25弘0申) 是由日本住友制药公司与英国ICI 制药公司共同 开发的第二代碳青霉烯抗生素,通过干扰细菌细胞壁的合成发挥杀菌作用,具有广谱耐酶的特 点[1_4]o 在美罗培南原料中常检测出杂质A 及杂质B,杂质A(C 17H 27N 3O 6S)为美罗培南四元内酰 胺环结构发生水解反应而形成,系美罗培南的降 解产物;杂质B(C 34H 50N 6O 10S 2)为美罗培南与杂质A 发生聚合反应而形成,系美罗培南的二聚体X 。

伊红美蓝琼脂(平板)说明书

伊红美蓝琼脂(平板)说明书

广东环凯微生物科技有限公司网址:地址:广州市黄埔区科学城神舟路788号邮编:510663传真:860288778876产品说明书Product Manual【产品名称】通用名称:伊红美蓝琼脂(平板)英文名称:Eosin Methlene Bule Agar Plate【产品编号与包装规格】产品编号产品类型包装规格024087即用型成品平板20个(90mm)/盒【产品用途】用于分离革兰氏阴性肠道菌特别是大肠菌群和粪大肠菌群。

【检验原理】蛋白胨提供碳源和氮源;乳糖是大肠菌群可发酵的糖类;磷酸氢二钾是缓冲剂;琼脂是培养基凝固剂;伊红和美蓝是抑菌剂和pH 指示剂,可抑制革兰氏阳性菌,在酸性条件下产生沉淀,形成紫黑色菌落或具黑色中心的外围无色透明的菌落。

75%酒精消毒外包装,在洁净环境下拆开包装袋,使用。

【质量控制】贮存于2-25℃,避光、干燥处;贮存期见产品标签。

【注意事项】1、注意无菌操作,避免外源污染。

2、质检报告可以登录环凯网站 ,打开“质检报告”页面,输入产品批号下载。

【废物处理】检测之后带菌物品置于121℃下高压灭菌30分钟后处理。

【执行标准】Q/HKSJ 03广东环凯微生物科技有限公司企业标准普通微生物培养基【说明版本】2019年11月23日【参考文献】1、GB4789.6-2016食品安全国家标准食品微生物学检验致泻大肠埃希氏菌检验2、GB4789.38-2012食品安全国家标准食品微生物检验大肠埃希氏菌计数3、GB/T5750.12-2006中华人民共和国国家标准食品安全国家标准生活饮用水标准检验方法微生物指标广东环凯微生物科技有限公司网址:地址:广州市黄埔区科学城神舟路788号邮编:510663传真:************-8619 ************8602************88778876。

杨梅素(杨梅树皮素,Myricetin)

杨梅素(杨梅树皮素,Myricetin)

杨梅素对照品【别名】【英文名】Myricetin【分子式】C15H10O8【分子量】318【CAS号】529-44-2【检测方式】高效液相色谱法HPLC≥80%/90%/98%【规格】20mg 50mg 100mg 500mg 1g (可根据客户需求包装) 【性状】本品为黄色针状晶体【作用与用途】本品用于含量测定。

【提取来源】本品为杨梅科杨梅属植物杨梅Myrica rubra (Lour.)Sieb. et Zucc.,的果实。

【药理性质】熔点为324.0~325.5℃,溶于甲醇,乙醇,丙酮,乙酸乙酯,微溶于水,难溶于氯仿、石油醚,置于空气中易氧化变绿。

【用法】色谱条件:, 流动相:乙腈-甲醇-水-磷酸(17.5∶17.5∶65∶1.3);检测波长360 nm(仅供参考)【贮藏方法】2-8°C,避光保存Manufacturer and Wholesale :Chinese herb medicine,Plantextract,Raw Herbs,Dried Herbs,V eterinary Medincine,Granulated,Powdered,Slice,Pills,SpicesPlant Extracts ,Herbal Supplements follows:1.Cas No: 90045-36-6 银杏叶提取物Ginkgo Biloba Extract ,Ginkgo Leaf(Ginkgo folium extract) 24/6, EGb 7612. Cas No:84929-27-1葡萄籽提取物原花青素Grape Seed Extract, Grape Skin Extract Polyphenols OPC 95% UV3. Cas No: 102518-79-6千层塔提取物石杉碱甲Huperzine Serrate Extract, Huperzine A 1%,99% HPLC4. Cas No: 529-44-2 杨梅提取物杨梅树皮素杨梅素杨梅苷Bayberry Bark Extract, Myricetin 80% ,90%,98% HPLC5. Cas No: 90045-38-8 人参提取物Ginseng Root Extract ,Ginsenosides 80% UV6. Cas No:50647-08-0 西洋参根提取物American Ginseng Root Extract(Panax quinquefolium)Ginsenosides 20-30%HPLC.7. Cas No 84082-34-8越橘提取物Bilberry Extract ,Anthocyanidins 25%UV.8. Cas No 22888-70-6;65666-07-1 水飞蓟提取物水飞蓟素Milk Thistle Extract(Silybum marianum extract) 30% Silybin HPLC.9. Cas No 501-36-0 虎杖提取物白藜芦醇iant knotweed extract ,Resveratrol 50% ,99% HPLC.10.Cas No 27200-12-0 藤茶提取物二氢杨梅素Vine Tea Extract ,Dihydromyricetin 90%,98% HPLC.11.Cas No 28957-04-2 冬凌草提取物冬凌草甲素Oridonin extract,Blushred Rabdosia Extract 1%,99% HPLC.12.Cas No 1399-64-0, 90045-47 匙羹藤、武靴藤提取物Gymnema sylvestre extract ,Gymnemic Acid 25%;10:112.Cas No 115939-25-8丹参提取物Salvia root extract,Dan-shen Extract,Salvianolic acid B,1-10%Tanshinone 13.Cas No 23180-57-6 白芍提取物白芍苷White Peony Root Extract,Paeonia lactiflora Palls,Paeoniflorin 1-95%14.Cas No 489-32-7 淫羊藿提取物淫羊藿甙Epimedium Extract ,Horny Goat Weed extract (icariin5%,10%,50%), icariins15.Cas No - 502-65-8番茄提取物番茄红素T omato extract,lycopene 5%,10%16.Cas No 10338-51-9 红景天提取物红景天甙Rhodiola Rosea extract,Rhodiola Root Extract ,Salidroside 1-10% HPLC.17.Cas No 84696-15-1, 生姜提取物Ginger Extract,Gingerols 2.5%,5% HPLC18.Cas No 138-59-0 八角茴香提取物莽草酸Star anise extract( Illicium verum extract) Shikimic Acid 98% HPLC 19.Cas No 4350-09-8加纳籽提取物Griffonia SeedExtract ,5-HTP 98% HPLC20.Cas No 458-37-7 姜黄素Turmeric Root Extract(Curcumin 95%) HPLC21.Cas No 84650-60-2绿茶提取物Green tea extract , T ea polyphenol 1-99% HPLC22.Cas No 574-12-9大豆提取物大豆异黄酮Soy Bean Extract, soflavones 40% HPLC23.Cas No 68916-91-6甘草提取物Licorice Extract 21% HPLC 23.Cas No34540-22-2 积雪草提取物积雪草甙Gotu Kola Extract,Centella Asiatica Extract ,Asiaticoside 10-70%23.Cas No 84082-80-4贯叶连翘提取物金丝桃素St.John's Wort Extract, Hypericin 0.3% HPLC24.Cas No 19130-96-2 桑叶提取物1-脱氧野尻霉素Mulberry Leaf Extract , 1-DNJ 1%-10% HPLC25.Cas No 91771-33-4 竹叶黄酮Bamboo Leaf extract ,Flavonoids 40%,80%26.Cas No 633-65-8 盐酸小檗碱Baikal Skullcap Extract ,Berberine Chloride 97%27 Cas No 84604-15-9锯叶棕榈脂肪酸Saw palmetto extract ,25% fatty acids28 Cas No 68797-35-3 甘草酸二钾Dipotassium Glycyrrhizinate extract 98%29 Cas No 138-52-3 白柳皮提取物水杨甙White Willowbark salicin 98%30 Cas No8012-96-2 吐根浸膏Ipecac Extract 2% 4% 8%31 Acai巴西莓提取物Berry Extract 5% 10%================================================ =========================We are sure that you will find us as your ideal supplier with consistent quality most competitive price. I m looking forward to your reply!Sincerely,------------------------------------------------------------------------------- product: Plant Extracts and Raw Material,Natural herbs,medicinal herbs,Herbal Supplements,Spices,Vitamins------------------------------------------------------------------------------- Manufacturer :Ningbo Dekang Biochem Co., Ltd.Natural productsArthur LeeTel: +86-189-5821-4967,Mobile: +86-135-6634-7633MSN:hy651025@E-mail:liqingliang_2008@AIM:herbextractsSkype: plantextracts--------------------------------------------------------------------------------。

烷基化试剂

烷基化试剂

鸟嘌呤 Guanine
O HN H2N
N DNA Monoalkylated adduct
N DNA
Guanine-Guanine link
Once alkylation occurs, the alkylated sites become prone to cleavage
2. Melphalan (美法伦)
O O N P HN
Cl
Cyclophosphamide (环磷酰胺)
Cl O O N P HN Cl CYP450 Liver Cl Cl O O N P HN OH Cl normal tissue normal tissue Cl O O N P HN Cl O Cl Cl O ON P + NH2 O H alkylating group Tumor Non enzymatic Cl O O N P NH2 Cl OH O Cl O O N P NH2 H O
Cl N Cl
H2 N COOH
L-
L-Phenylalanine mustard or L-PAM L-PAM can be preferentially transported into cells, with the assistance of L-amino acid active transporter
Cl
H
vinyl diazotic acid -OH N2
N N N O cyclic oxazolidine
Reactive species
+ H2O -CO2 H2N Cl
Reactive species
H2C CH vinyl cation
Reactive species

丙酮酸乙酯抗肿瘤作用及其机制的研究进展

丙酮酸乙酯抗肿瘤作用及其机制的研究进展

丙酮酸乙酯抗肿瘤作用及其机制的研究进展李松(综述);杭春华(审校)【摘要】Ethyl pyruvate ( EP) is a stable lipophilic ester derivative of pyruvate with many pharmacological actions confirmed by researches , the anti-tumor effects of EP has attracted the attention of many domestic and foreign scholars .EP exerts antitumor activi-ty through several ways , such as inhibiting proliferation , inducing apoptosis , inhibiting angiogenesis , blocking cell cycle .This paper briefly reviews the rencent findings of antitumor function of EP .%丙酮酸乙酯( ethyl pyruvate , EP)是一种丙酮酸酯类衍生物,具有广泛的药理作用,其抗肿瘤作用的研究日益受到国内外学者关注。

它可通过抑制细胞增殖、诱导细胞凋亡、抗血管生成及阻滞细胞周期等机制发挥抗肿瘤作用,现就近年来EP抗肿瘤作用的研究进展进行简要综述。

【期刊名称】《医学研究生学报》【年(卷),期】2014(000)010【总页数】3页(P1111-1113)【关键词】丙酮酸乙酯;抗肿瘤作用;作用机制【作者】李松(综述);杭春华(审校)【作者单位】210002 南京,南方医科大学南京临床医学院南京军区南京总医院神经外科;210002 南京,南方医科大学南京临床医学院南京军区南京总医院神经外科【正文语种】中文【中图分类】R979.10 引言自1970年以来,肿瘤在我国的发病率和病死率逐年升高,其中恶性肿瘤是导致我国城乡居民死亡的第一大病因[1]。

德谷门冬双胰岛素注射液治疗2_型糖尿病临床效果及安全性探讨

德谷门冬双胰岛素注射液治疗2_型糖尿病临床效果及安全性探讨

DOI:10.16658/ki.1672-4062.2023.17.098德谷门冬双胰岛素注射液治疗2型糖尿病临床效果及安全性探讨林生,谢平,陈予福州市长乐区人民医院内分泌科,福建福州350200[摘要]目的研究德谷门冬双胰岛素注射液治疗2型糖尿病的临床效果及安全性。

方法选取于2022年7月—2023年4月福州市长乐区人民医院收治的2型糖尿病患者98例为研究对象,采用随机抓阄法分为两组,每组49例。

两组均联用常规降糖药物治疗,对照组采用甘精胰岛素注射液治疗,观察组采用德谷门冬双胰岛素注射液治疗。

对比两组临床治疗效果、临床症状好转时间和胰岛素用量情况、糖代谢指标、胰岛素功能指标、不良反应发生情况、心血管不良事件发生情况。

结果观察组总有效率高于对照组,差异有统计学意义(P<0.05)。

观察组尿酮体转阴时间、血糖达标时间、胰岛素用量均优于对照组,差异有统计学意义(P< 0.05)。

观察组空腹血糖、餐后2 h血糖、糖化血红蛋白均低于对照组,差异有统计学意义(P<0.05)。

观察组胰岛β细胞功能指数高于对照组,胰岛素抵抗指数、空腹胰岛素低于对照组,差异有统计学意义(P<0.05)。

两组恶心呕吐、倦怠乏力、低血糖总发生率比较,差异无统计学意义(P>0.05)。

两组心绞痛、心力衰竭总发生率比较,差异无统计学意义(P>0.05)。

结论德谷门冬双胰岛素注射液治疗2型糖尿病临床效果显著优于甘精胰岛素注射液,但是治疗安全性无显著变化。

[关键词] 2型糖尿病;德谷门冬双胰岛素注射液;不良反应;心血管不良事件[中图分类号] R59 [文献标识码] A [文章编号] 1672-4062(2023)09(a)-0098-04Discussion on the Clinical Effect and Safety of Insulin Degludec and Insu⁃lin Aspart Injection in the Treatment of Type 2 Diabetes MellitusLIN Sheng, XIE Ping, CHEN YuDepartment of Endocrinology, Changle District People's Hospital, Fuzhou, Fujian Province, 350200 China[Abstract] Objective To study the clinical effect and safety of insulin degludec and insulin aspart injection in the treatment of type 2 diabetes mellitus. Methods A total of 98 patients with type 2 diabetes admitted to Fuzhou Changle District People's Hospital from July 2022 to April 2023 were selected as the study objects and divided into two groups with 49 cases in each group by random lottery method. Both groups were treated with conventional hypoglycemic drugs, the control group was treated with insulin glargine injection, and the observation group was treated with Degu asparton double insulin injection. The clinical therapeutic effect, time of improvement of clinical symptoms, insulin dosage, glucose metabolism index, insulin function index, occurrence of adverse reactions and cardiovascular adverse events were compared between the two groups. Results The total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). The time of urine ketone body turning negative, blood glucose reaching standard and insulin dosage in observation group were better than those in control group, and the differences were statistically significant (P<0.05). Fasting plasma glucose, 2-hour postprandial blood glucose and glycated hemoglobin in the observation group were lower than those in the control group, and the differences were statistically significant (P<0.05). The function index of islet β cells in observation group was higher than that in control group, the insulin resistance index and fasting insulin was lower than that in control group, the dif⁃ference was statistically significant (P<0.05). There was no statistically significant difference in the total incidence of [作者简介]林生(1981-),男,本科,副主任医师,研究方向为糖尿病及其并发症的相关临床研究。

乙酰胆碱酯酶抑制剂

乙酰胆碱酯酶抑制剂

上海应用技术学院研究生课程《高等天然产物化学》试卷2014 / 2015 学年第1 学期课程代码:NX0702013论文题目:乙酰胆碱酯酶抑制剂的研究进展姓名:芮银146061414康满满146061409专业:制药工程学院:化工学院乙酰胆碱酯酶抑制剂的研究进展芮银,陈祎桐,康满满摘要:本文阐述了乙酰胆碱酯酶抑制剂(AChEI)的研究进展,介绍了用于药物治疗的乙酰胆碱酯酶抑制剂的各种来源如植物、微生物等,及其抑制乙酰胆碱的活性物质。

在此基础上,总结了几种现代分析技术,对AChEIs进行筛选,大大加快AD药物资源的开发利用进程。

这些方法主要有基于比色法的Ellman's法及相关的改进方法、薄层显色法、荧光显色法、电喷雾质谱法等。

但是,到目前为止,现代分析技术在AD药物资源中的应用还处在起步阶段。

关键词:乙酰胆碱酯酶抑制剂,筛选方法,薄层显色法,荧光显色法The progress of acetylcholinesteraseinhibitorsRui Yin, Chen Yitong, Kang ManmanAbstract:In this artical, the research elaborates progress of acetylcholinesterase inhibitors (AChEI), and introduces a variety of sources for drug treatment acetylcholinesterase inhibitors such as plants, microorganisms, and its active ingredients. On this basis, the review summarizes several modern analytic techniques such as Ellman's method which based on the colorimetric method, TLC chromogenic method, fluorescent color method, Electrospray ionization mass spectrometry and so on. However, at present, the application of modern analytic techniques in AD drug resources is still in infancy.Key word: Acetylcholinesterase inhibitors, Screening Methods, TLC chromogenic method, Fluorescent color method目录摘要.................................................................................................错误!未定义书签。

羟基乙叉二膦酸MSDS

羟基乙叉二膦酸MSDS

PackingGroup? II
毒害物质数据 2809-21-4(Hazardous Substances Data)
生产的这类产品还有基他一些品种,例如氨基三亚甲基膦酸(ATMP): [CH2PO(OH)2]3N 以及乙二胺四亚甲基磷酸(EDTMP)等等。有机多 元膦酸是 60 年代后期开发、70 年代前后被确认的一类水处理剂,这 类处理剂的出现使水片理技术向前迈进了一大步。与机聚磷酸盐相 比,有机多无膦酸具有良药姨的化学稳定性、不易水解、能耐较高温 度和药剂量小且兼具缓和蚀垢 性能等特点。是一类阴极型缓蚀剂, 又是一类非化学当量阻垢剂。和其他水处理剂复合使用时,表现出理 想的协同效应。对许多金属离子如钙、镁、铜、锌等具有优异的螯合 能务,甚至对这些金属的无机盐类如 CaSO4、CaCO3、MgSiO3 等也有
关 剂;电镀化学品;Industrial/Fine Chemicals;INORGANIC & ORGANIC 类 CHEMICALS;Analytical Chemistry;Ligands for Pharmaceutical 别 Research;Radiopharmaceutical Chemistry (Chelating : Reagents);Phosphonate antiscalant;organophosphorus compound Mo l 文 件 :
较好的去活化作用,因此大量应用于水处理技术。该品低毒,小白鼠 皮下注射 LD50 为 kg。
用 是锅炉和换热器的阻垢剂和缓蚀剂、无氰电镀的络合剂、皂用螯合剂、 途? 金属和非金属的清洗剂
用 磷酸化试剂,用于被保护的丝氨酸和吡喃糖。
途?
生产 由三氯化磷与冰醋酸混合后,加热、蒸馏,得乙酰氯(见 00510), 方 再与亚磷酸反应制得。市售品为以水稀释为含量 50%的粘稠液体。每 法? 吨产品消耗三氯化磷(95%)931kg,冰醋酸 591kg。

依达拉奉右莰醇治疗缺血性脑卒中的研究进展

依达拉奉右莰醇治疗缺血性脑卒中的研究进展

- 179 -①滨州医学院附属医院神经内科 山东 滨州 256600通信作者:鹿树军依达拉奉右莰醇治疗缺血性脑卒中的研究进展席娅琳① 汪临华① 鹿树军① 【摘要】 缺血性脑卒中是脑血管疾病中的常见病,严重可导致高级认知及运动障碍,甚至死亡。

缺血性脑卒中的治疗方法主要包括早期溶栓和保护神经细胞等治疗,然而目前神经保护剂的临床疗效有待考证,大多数神经保护剂仍未得出有益的证据。

新型双靶点复合型神经保护剂依达拉奉右莰醇(ED)可抑制诱导型一氧化氮合酶(iNOS)和肿瘤坏死因子-α(TNF-α)的表达,降低自由基过氧化亚硝基阴离子(ONOO -)水平,从而改善缺血性脑卒中所致的神经损伤症状、功能障碍及活动障碍,本文将对ED 的作用机制及其应用发展做一综述,并对ED 的临床应用进行展望,为后续的用药提供指导。

【关键词】 缺血性脑卒中 自由基清除剂 神经保护剂 依达拉奉右莰醇 Research Progress of Edaravone Dexborneol in the Treatment of Ischemic Stroke/XI Yalin, WANG Linhua, LU Shujun. //Medical Innovation of China, 2024, 21(10): 179-183 [Abstract] Ischemic stroke is a common type of cerebrovascular disease that can lead to advanced cognitive and motor deficits and even death. The treatment of ischemic stroke mainly includes early thrombolysis and neuroprotection. However, the clinical efficacy of neuroprotective agents remains to be verified, and most neuroprotective agents have not yet received useful evidence. Edaravone Dexborneol (ED), a new dual-target neuroprotective agent, can inhibit the expression of inducible nitric oxide synthase (iNOS) and tumor necrosis factor-α(TNF-α), reduce the level of peroxynitrite anion (ONOO -), and improve the symptoms of nerve injury, dysfunction, and activity disorder caused by ischemic stroke. This article will review the mechanism of ED and its application development, and prospect the clinical application of ED, so as to provide guidance for subsequent medication. [Key words] Ischemic stroke Free radical scavenger Neuroprotective agent Edaravone Dextrogenol First-author's address: Department of Neurology, Binzhou Medical University Hospital, Binzhou 256600, China doi:10.3969/j.issn.1674-4985.2024.10.041 脑卒中已成为我国居民寿命的“第一杀手”,其中,急性缺血性脑卒中(acute ischemic stroke,AIS)约占我国脑卒中的70%,为最常见的卒中类型[1-2]。

317种化学物质IDLH(立即威胁生命和健康浓度)

317种化学物质IDLH(立即威胁生命和健康浓度)

317种化学物质IDLH(立即威胁生命和健康浓度)附录B:IDLH浓度本附录提供的IDLH浓度采纳自美国国家职业安全卫生研究所(NIOSH)正式出版物DHHS No。

90-117版本的IDLH浓度。

具体浓度请参见表B.1.表B.1 IDLH浓度序号。

污染物中文名称。

污染物英文名称。

浓度(PPM)系数(2()C)。

IDLH浓度(mg/m3)(20C)1.乙醛。

acetaldehyde。

acetic aldehyde。

10,000.18,0002.乙酸,醋酸。

acetic acid。

1,000.2,5003.乙酸酊,醋酸酊。

acetic anhydride。

1,000.4,2004.丙酮,阿西通。

acetone。

20,000.18,0005.乙腊,甲基割。

acetonitrile。

methyl cyanide。

4,000.6,8006.四溴乙烷。

acetylene tetrabromide。

tetrabromoethane。

6.17.乙烯醛。

acrolein。

allyl aldehyde。

500.2,5008.丙烯睛,乙烯基睛。

acrylonitrile。

vinyl cyanide。

150.4,2009.艾氏剂。

aldrin。

300.18,00010.烯丙醇。

allyl alcohol。

270.6,80011.烯丙卤代烷。

allyl chloride。

500.1,00012.烯丙环氧乙烷。

allyl glycidyl ether。

4,000.4,20013.2-氨基吡啶。

2-aminopyridine。

9,000.5,41014.氨。

ammonia。

100.5,41015.硫酸铵。

ammonium sulfamate。

14.37.3.87016.戊酸乙酯。

n-amyl acetate。

40.1,00017.异戊酸乙酯。

sec-amyl acetate。

95.2,50018.氨基苯。

aminobenzene。

伊立替康分子量

伊立替康分子量

伊立替康分子量
伊立替康分子量是多少?这是很多人关心的问题。

作为一款常被用于治疗糖尿病的口服药物,伊立替康的分子量对药物的疗效和副作用产生重要影响。

1. 什么是伊立替康?
伊立替康(Empagliflozin)是一种双吡嗪类抑制剂,用于治疗2型糖尿病。

它起到促进肾脏排泄过多的糖分,从而降低血糖水平的作用。

2. 伊立替康的分子结构
伊立替康的化学名为(编号:761423-87-4)-(S)-1,5-二羟甲基-4-(4-甲基苯基)-2- [4-(三氟甲基)苯氧]吡咯烷-3-羧酸二乙酯。

其分子式为C23H27F3O7,分子量为僅僅450.46。

3. 伊立替康分子量和药效的关系
伊立替康分子量较小,因此可以更容易地进入肾脏和其他器官。

这种小分子量也是许多糖尿病患者更喜欢选择口服药物的原因之一。

由于其分子量越小,越容易口服,被吸收和运输到靶细胞位置。

4. 小结
伊立替康分子量为僅僅450.46,这使得它能够更容易地进入肾脏和其他器官,发挥其治疗糖尿病的作用。

因此,掌握伊立替康分子量是非常重要的,关于伊立替康的更多知识应该通过各种途径,包括药品说明书和医疗专业人员来获取。

2-甲氧基乙酸乙酯安全技术说明书MSDS

2-甲氧基乙酸乙酯安全技术说明书MSDS

第一部分化学品及企业标识化学品中文名:2-甲氧基乙酸乙酯化学品英文名:2-methoxyethyl acetate;methylglycol acetate;methyl cellosolve acetate;acetic acid ethylene glycol monomethyl ether ester化学品别名:乙酸甲基溶纤剂;乙二醇甲醚乙酸酯;乙酸乙二醇甲醚CAS No.:110-49-6EC No.:203-772-9分子式:C5H10O3第二部分危险性概述紧急情况概述液体。

易燃,其蒸气与空气混合,能形成爆炸性混合物。

GHS危险性类别根据GB30000-2013化学品分类和标签规范系列标准(参阅第十六部分),该产品分类如下:易燃液体,类别3;生殖毒性,类别1B。

标签要素象形图警示词:危险危险信息:易燃液体和蒸气,可能对生育能力或胎儿造成伤害。

预防措施:使用前取得专业说明。

在阅读并明了所有安全措施前切勿搬动。

远离热源、热表面、火花、明火以及其它点火源。

禁止吸烟。

保持容器密闭。

容器和接收设备接地和等势联接。

使用不产生火花的工具。

采取措施,防止静电放电。

戴防护手套/穿防护服/戴防护眼罩/戴防护面具。

事故响应:如接触到或有疑虑:求医/就诊。

如皮肤(或头发)沾染:立即去除/脱掉所有沾染的衣服。

用水清洗皮肤或淋浴。

安全储存:存放处须加锁。

存放在通风良好的地方。

保持低温。

废弃处置:按照地方/区域/国家/国际规章处置内装物/容器。

物理化学危险:易燃液体,其蒸气与空气混合,能形成爆炸性混合物。

健康危害:吸入该物质可能会引起对健康有害的影响或呼吸道不适。

意外食入本品可能对个体健康有害。

通过割伤、擦伤或病变处进入血液,可能产生全身损伤的有害作用。

眼睛直接接触本品可导致暂时不适。

环境危害:请参阅SDS第十二部分。

第三部分成分/组成信息√物质混合物危险组分浓度或浓度范围CASNo.2-甲氧基乙酸乙酯>=99.0 110-49-6第四部分急救措施皮肤接触:立即脱去污染的衣物。

艾力

艾力

作用特点(二)
以CPT-11为基础的联合化疗方案显示出较传统方案 更好的临床效益----胃癌
2005年ASCO报道:FOLFIRI方案一线治疗晚期胃癌的研究显示,客 观反应率为36%,中位进展期和中位生存期分别为9.3个月和12.6 个月(ASCO2005 #4164) CPT-11联合多西他赛治疗转移性胃癌的Ⅱ期临床初步结果显示:总 有效率为78% ,TTP为5.4个月(ASCO2005 #32) CPT-11+L-OHP+5-FU/CF联合方案(FOLFOXIRI)一线治疗晚期转移
作用特点(二)
以CPT-11为基础的联合化疗方案显示出较传统方 案更好的临床效益-----SCLC CPT-11+卡铂对比依托泊苷+卡铂,可显著延长SCLC伴广泛 性疾病患者的总生存期,且耐受性好(2007ASCO #7523) N=220, IC组/EC组:OS为8.5M/7.1M(P=0.04) 1年生存率:35%/28%,CR:18例/7例
2004年,FDA还批准CPT11+Avastin用于大肠癌
一线治疗,CPT11+C225用于大肠癌二线治疗。 CPT-11与铂类联合,是一线治疗晚期肺癌的理想方案。
CPT-11与紫杉醇、铂类联合可用于晚期胃癌、妇科肿瘤等 治疗
CPT-11单药治疗吉西他滨耐药的进展期胰腺癌有令人鼓舞 的抗肿瘤活性(中位TTP为4。0个月)2007 #15111
57600 60000 艾力 50000 40000 28480 30000 20400 20000 10000 0 100mg制剂每疗程价格(元) 40mg制剂每疗程价格(元) 开普拓 39360
双周方案180mg/m2 d1,14天为一周期,四周期为一疗程

上海成捷化学,咪唑型离子液体

上海成捷化学,咪唑型离子液体
1057409-91-2

1-癸基-3-甲基咪唑甲磺酸盐
不溶
1-癸基-3-甲基咪唑双氰胺盐
不溶
1-癸基-3-甲基咪唑硫氰酸盐
847499-75-6
不溶
氯化1-十二烷基-3-甲基咪唑
114569-84-5

溴化1-十二烷基-3-甲基咪唑
188589-32-4

1-十二烷基-3-甲基咪唑四氟硼酸盐
244193-59-7

1-乙烯基-3-甲基咪唑六氟磷酸盐
不溶
1-乙烯基-3-甲基咪唑六氟锑酸盐
不溶
1-乙烯基-3-甲基咪唑三氟甲磺酸盐
187387-89-9

1-乙烯基-3-甲基咪唑双三氟甲磺酰亚胺盐
不溶
1-乙烯基-3-甲基咪唑高氯酸盐
1072788-91-0

1-乙烯基-3-甲基咪唑硝酸盐
1072788-90-9

1-乙烯基-3-甲基咪唑甲磺酸盐
521304-36-9

1,3-二甲基咪唑对甲苯磺酸盐
54722-21-3

1,3-二甲基咪唑三氟乙酸盐
174899-93-5

溴化1-乙基-3-甲基咪唑
65039-08-9

碘化1-乙基-3-甲基咪唑
35935-34-3

1-乙基-3-甲基咪唑硫酸乙酯盐
342573-75-5

1-乙基-3-甲基咪唑硫酸甲酯盐
不溶
1-己基-3-甲基咪唑三氟甲磺酸盐
460345-16-8

1-己基-3-甲基咪唑双三氟甲磺酰亚胺盐
916729-96-9
不溶
1-己基-3-甲基咪唑磷酸二氢盐
  1. 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
  2. 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
  3. 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。

MSDS
1 Composition
7 Accident Release Measure
Product Name:LY2940680
Chemical Name:
PROCEDURE(S) OF PERSONAL PRECAUTION(S)-Wear respirator, chemical safety goggles, rubber boots, and heavy
rubber gloves.METHODS FOR CLEANING UP-Sweep up, place in a bag and hold for waste disposal. Avoid raising dust. Ventilate area and
wash spill site after material pickup is complete.
Benzamide, 4-fluoro-N-methyl-N-[1-[4-(1-methyl-1H-pyrazol-5-yl)-1-phthalazinyl]-4-piperidinyl]-2-(trifluoromethyl)-
CAS No.:1258861-20-9
8 Accident Release Measure
Appearance:White to off-white(Solid)Formula:C26H24F4N6O
9 Toxicological Information
Solubility:
To the best of our knowledge, the chemical, physical, and
toxicological properties have not been thoroughly investigated.
No data available.
p p p p DMSO ≥0.8mg/mL Water <1.2mg/mL
Ethanol ≥1.8mg/mL
2 Handling and Storage
10 Regulary Information
3 Stability and Reactivity
11Disposal Considerations
CLASSIFICATION- Substance not yet fully tested.SAFETY PHASES- 26-36 (In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing.) 36/37/38 (Irritating to eyes,respiratory system and skin.)
STABILITY- Stable under normal handling conditions.HANDLING- Do not breathe dust. Avoid contact with eyes,
skin,and clothing.Avoid prolonged or repeated exposure.STORAGE- Store in a properly sealed container store at -20℃,shelflife is 2 years.
11 Disposal Considerations 4 Hazards Identification
12 Transport Information
5First Aid RID/ADR- Non-hazardous for road transport. IMDG- Non-hazardous for sea transport.IATA - Non-hazardous for air transport.
As specific country, federal, state and local environmental
regulations vary and change frequently we suggest you contact a local, authorized waste disposal contractor for adequate disposal.
Special indication of hazards to humans and the environment.Irritating to eyes, respiratory system and skin.
MATERIALS TO AVOID- Strong oxidizing agents.REACTIVITY- May emit toxic gasses like Carbon monoxide,Carbon dioxide, Nitrogen oxides upon thermal decomposition.
5 First Aid
13 Other Information
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. Medchemexpress LLC shall not be held liable for any damage resulting from h dli f t t ith th b d t
INHALATION- If inhaled, remove to fresh air. If not breathing give, artificial respiration. If breathing is difficult, give oxygen.SKIN CONTACT- In case of contact, immediately wash skin with
soap and copious amounts of water.EYE CONTACT- In case of contact, immediately flush eyes with
copious amounts of water for at least 15 minutes.INGESTION- If swallowed, wash out mouth with water provided person is conscious. Call a physician.
6 Fire Fighting Measures
handling or from contact with the above product.
EXTINGUISHING MEDIA Water spray- Carbon dioxide, dry chemical powder, or appropriate foam.
SPECIAL RISKS Specific Hazard(s)- Emits toxic fumes under fire conditions. SPECIAL PROTECTIVE EQUIPMENT FOR FIREFIGHTERS Wear self-contained breathing apparatus and protective clothing Caution: Not fully tested. For research purposes only
Medchemexpress LLC
to prevent contact with skin and eyes.
18W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S A
E m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o m。

相关文档
最新文档